Epistem plc, a UK biotechnology and contract research company, will present results from their latest plucked hair biomarker study at the ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer, Hollywood FL, United States on Friday 31st October 2008.
Epistem to Present Plucked Hair Biomarker Data at ASCO-NCI-EORTC Meeting
MANCHESTER, UNITED KINGDOM --(Marketwire-October 27, 2008) - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present results from their latest plucked hair biomarker study at the ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer, Hollywood FL, United States on Friday 31st October 2008. Dr Ged Brady will present data to show that cell cycle genes, previously identified in breast tumour tissue and linked to clinical outcome in breast cancer patients, are also differentially expressed in single intact and dissected plucked hairs from healthy normal volunteers.
The study demonstrates the viability of monitoring gene expression in single human hairs to identify expression profiles relevant to tumour biology. Using a minimally invasive approach to obtain sensitive and reproducible data, the results support the case that plucked hairs are a suitable surrogate tissue for biomarker identification and analysis in clinical oncology trials.
The abstract will be available on request following the presentation (poster session C 5:30 – 7:00 pm).
For further information on the Company, please visit www.epistem.co.uk or contact:
Dr. Danielle Hargreaves +44 (0)161 606 7258
Public Relations +44 (0) 7920 815603
Epistem plc. info@epistem.co.uk
Mike Wort / Anna Dunphy +44 (0) 207 861 3838
Financial PR/IR
De Facto Communications
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.